| Application no. and date | 11761051.9 (espacenet) (Federated) (European Patent Register), 20110919 | | Patent/reg. no. and date | DK/EP 2624859, 20170301 | | Publication date | 20130814 | | Priority no. and date | US 390224 P, 20101006 | | EP pub. no. and date |
EP 2624859 20130814 | | Effective date | | | Applicant/owner | Medimmune Limited, Milstein Building Granta Park
Cambridge, Cambridgeshire CB21 6GH, GB | | Applicant ref. no. | Med BLOOD-500-EP-EPT | | Inventor | LOVGREN, Ann, AstraZeneca R&D
Pepparredsleden 1-3
S-43183 Mölndal, SE,
HANSSON, Kenny, AstraZeneca R&D
Pepparredsleden 1-3
S-43183 Mölndal, SE | | Representative | RWS Group, RWS Compass House
Vanwall Business Park, Vanwall Road
Maidenhead, Berkshire
SL6 4UB, GB | | Opponent | | | IPC Class | A61K 38/36 (2006.01) , A61K 38/48 (2006.01) , A61P 7/04 (2006.01) | | Title | FAKTOR II ALENE ELLER I KOMBINATION MED ANDRE FAKTORER TIL BEHANDLNG AF NEDSAT HÆMOSTASE I FORBINDELSE MED FORTYNDINGSKOAGULOPATI | | Int. application no. | EP2011066241 | | Int. publication no. | WO2012045569 | | Related patent (certificate) | | | Status | Bortfaldet | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
